Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 3
1(100.0%)
1Total
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06713837Phase 3Recruiting

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Role: collaborator

NCT06459024Recruiting

Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Role: collaborator

NCT06172712Recruiting

COPD Exacerbation Modelling Using Unobtrusive Sensors - the TOLIFE Clinical Study A

Role: collaborator

All 3 trials loaded